Key facts
- This page summarizes Eric Easom's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Feb 2023, 16:36.
Eric Easom - 23 Feb 2023 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ANTX
- Reported as of
- 23 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2023, 16:36:06 UTC
- Prior SEC filing
- 14 Nov 2022
- Next SEC filing
- 15 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lucy Day, Attorney-in-Fact for Eric Easom
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Easom filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 24 Feb 2023.
Change
- Previous filing in this sequence was filed on 14 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANTX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +267,650
- Change %
- Price
- $0.000000
- Shares after
- 267,650
- Date
- 23 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 267,650
- Exercise price
- $11.99
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.